Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
178 USD | +8.23% | +9.48% | +44.95% |
12:39pm | KKR & Co, CrowdStrike, GoDaddy to Join S&P 500 Index on June 24 | MT |
May. 23 | Krystal Biotech Insider Sold Shares Worth $3,282,690, According to a Recent SEC Filing | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 72.72 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- The company is highly valued given the cash flows generated by its activity.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+44.95% | 4.7B | C | ||
+19.07% | 125B | B+ | ||
+14.16% | 108B | B+ | ||
-7.49% | 24.21B | B+ | ||
+2.07% | 22.78B | B | ||
-10.79% | 17.96B | A- | ||
-41.74% | 16.43B | A- | ||
-13.83% | 16.37B | B | ||
+2.47% | 13.58B | C+ | ||
+28.03% | 11.66B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KRYS Stock
- Ratings Krystal Biotech, Inc.